Results 91 to 100 of about 72,544 (286)

Pediatric Emergency Medicine Didactics and Simulation (PEMDAS): Serotonin Syndrome

MedEdPORTAL, 2020
Introduction Serotonin syndrome is caused by an accumulation of serotonin in the body from drug interactions or overdose of serotonergic medications, including commonly used antidepressants.
Corinne Shubin, Shweta Iyer, Jean Pearce, Benjamin Lang, Isabel Gross, Daisy Ciener, Suzan Mazor, Ashley Keilman, Anita Thomas   +8 more
doaj   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

Clinical Pharmacology &Therapeutics, EarlyView.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore, Melissa S. Bourque, Andreas Halman, José A. G. Agúndez, Cynthia A. Prows, Keiko Hikino, Matthias Schwab, Carolyn J. Oxencis, Dharmisha Chauhan, Meta H.M. Diekstra, Susie E. Long, Gillian C. Bell, Andrea Gaedigk, Michelle Whirl‐Carrillo, Teri E. Klein, Kelly E. Caudle, Rachel Conyers   +16 more
wiley   +1 more source

β-Amyloid(1-42)-Induced Cholinergic Lesions in Rat Nucleus Basalis Bidirectionally Modulate Serotonergic Innervation of the Basal Forebrain and Cerebral Cortex

Neurobiology of Disease, 2001
Ample experimental evidence suggests that β-amyloid (Aβ), when injected into the rat magnocellular nucleus basalis (MBN), impels excitotoxic injury of cholinergic projection neurons.
Tibor Harkany, Sheila O'Mahony, Jan Keijser, John P. Kelly, Csaba Kónya, Zsolt A. Borostyánkői, Tamás J. Görcs, Márta Zarándi, Botond Penke, Brian E. Leonard, Paul G.M. Luiten   +10 more
doaj   +1 more source

L-Tetrahydropalamatine: A Potential New Medication for the Treatment of Cocaine Addiction [PDF]

, 2012
Levo-tetrahydropalmatine (l-THP) is an active constituent of herbal preparations containing plant species of the genera Stephania and Corydalis and has been approved and used in China for a number of clinical indications under the drug name Rotundine ...
Mantsch, John R., Wang​, Jia Bei
core   +1 more source

Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish Model. [PDF]

, 2020
Dravet syndrome is a catastrophic epilepsy of childhood, characterized by cognitive impairment, severe seizures, and increased risk for sudden unexplained death in epilepsy (SUDEP).
Anvar, Mana, Baraban, Scott C, Griffin, Aliesha, Hamling, Kyla   +3 more
core   +1 more source

Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology. [PDF]

, 2014
Maladaptive plasticity can be defined as behavioral loss or even development of disease symptoms resulting from aberrant plasticity changes in the human brain.
Ahmed, Ananth, Aron, Aron, Baldessarini, Breakefield, Brooks, Byl, Calabresi, Calabresi, Carta, Casey, Casey, Castrén, Cenci, Cenci, Cerasa, Cerasa, Cerasa, Cerasa, Cerasa, Clarke, Crow, Crow, de la Fuente-Fernandez, de la Fuente-Fernandez, Fahn, Ganos, Gottwald, Heckers, Jankovic, Jellinger, Jenner, Kishore, Kishore, Koch, Koch, Koch, Li, Marsden, McEwen, Morgante, Nambu, Obeso, Pakkenberg, Peralta, Picconi, Quartarone, Rascol, Rylander, Salgado-Pineda, Sawada, Sgambato-Faure, Sigwald, Spencer, Teo, Vernon, Vernon, Zesiewicz   +58 more
core   +2 more sources

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović, Kent W. Nilsson, Robert Fredriksson, Helgi B. Schiöth, Thiago C. Moulin   +4 more
wiley   +1 more source

Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics [PDF]

, 2012
Introduction: In order to assess the significance of drug levels measured in intensive care medicine, clinical and forensic toxicology, as well as for therapeutic drug monitoring, it is essential that a comprehensive collection of data is readily ...
Andresen, Hilke, Iwersen-Bergmann, Stefanie, Schmoldt, Achim, Schulz, Martin   +3 more
core   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

MPTP-induced degeneration: interference with glutamatergic toxicity [PDF]

, 1994
Parkinson's disease (PD) is characterised by the progressive degeneration of nigrostriatal dopamine (DA) neurons resulting in the major symptoms of akinesia and rigidity.
Lange, Klaus W., Löschmann, P. A., Turski, L., Wachtel, H.   +3 more
core